Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease

University of Wisconsin (UW)

Status and phase

Completed

Phase 3

Phase 2

Conditions

Alzheimer Disease

Treatments

Drug: Raloxifene

Study type

Interventional

Funder types

Other

NIH

Identifiers

NCT00065767

1R01AG029624-01 (U.S. NIH Grant/Contract)

IRB M1285

IA0049

Details and patient eligibility

About

The aim of this study is to determine the effectiveness of treatment with raloxifene, an estrogen-like medication approved by the Food and Drug Administration for the treatment of osteoporosis, in improving memory and the ability to live independently in postmenopausal women with Alzheimer's disease.

Full description

The aim of this study is to determine the effectiveness of treatment with raloxifene, an estrogen-like medication (classified as Selective Estrogen Receptor Modulators (SER's)) approved by the Food and Drug Administration for the treatment of osteoporosis, in improving memory and the ability to live independently in postmenopausal women with Alzheimer's disease. Patients who volunteer for this study will need to visit the clinic 7 times (participate) over a period of five months and will receive either raloxifene or a harmless, inactive pill called a placebo. Neither the volunteers nor the study staff will know which type of pill a patient receives. Patients must be generally healthy and have mild-to-moderate dementia. There must be a patient caregiver who can watch for side effects and ensure that the patient takes the study pills on schedule over a period of three months.

Patients will undergo neuropsychological tests and an evaluation of the ability to live independently at each visit as well as laboratory evaluations, such as the taking of blood. Each visit will last approximately 3 hours. A total of 20 patients is being recruited to participate in this study at the University of Wisconsin.

Sex

Female

Ages

55 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Postmenopausal women with Alzheimer's disease and without other dementias (diagnosed by study staff or from an outside clinic)
Mini Mental Status Exam score greater than 15/30

Exclusion criteria